NASDAQ:JANX

Janux Therapeutics Q2 2026 Earnings Results & Report

Janux Therapeutics logo
$10.31 -0.40 (-3.73%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$10.40 +0.09 (+0.83%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Janux Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.35 versus the -$0.2513 consensus estimate, while revenue of $10.27 million fell short of the $19.08 million estimate by $8.81 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Janux Therapeutics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.2513
Beat/Miss
Missed by -$0.0987
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Janux Therapeutics Revenue Results

Actual Revenue
$10.27 million
Expected Revenue
$19.08 million
Beat/Miss
Missed by -$8.81 million
YoY Revenue Growth
N/A

Janux Therapeutics Q2 2026 Earnings FAQ

Janux Therapeutics (NASDAQ:JANX) reported earnings of -$0.35 per share for Q2 2026, missing the consensus estimate of -$0.2513. The report was announced on Thursday, August 6, 2026.

Janux Therapeutics reported revenue of $10.27 million for Q2 2026, against a consensus estimate of $19.08 million.

Janux Therapeutics Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More Janux Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email.

About Janux Therapeutics

Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors.

Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.

Based in San Diego, California, Janux was founded in 2017. The company is led by co-founder David Campbell, Ph.D., who serves as president and chief executive officer.

View Janux Therapeutics Profile